Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases

Frontline cemiplimab plus chemotherapy improved overall survival and progression-free survival compared with investigator’s choice of chemotherapy for patients with PD-L1–positive non–small cell lung cancer that has metastasized to the brain.

Related Keywords

Copenhagen ,Køavn ,Denmark ,Istinye ,Istanbul ,Turkey ,Alaska ,United States ,Alaskans ,American , ,European Lung Cancer Congress ,Istinye University Faculty Of Medicine ,Istinye University Faculty ,Lung Cancer ,American Indian ,Lung Cancer Congress ,Frontline Cemiplimab Plus Chemotherapy ,Patients With Pd L1 Positive Non Small Cell Lung Cancer ,Empower Lung 1 Trial ,Nct03088540 ,Saadettin Kılıçkap ,D ,